1988
DOI: 10.1016/s0272-6386(88)80206-3
|View full text |Cite
|
Sign up to set email alerts
|

Prospective Evaluation of a Dacron Cuffed Hemodialysis Catheter for Prolonged Use

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
122
0
5

Year Published

1997
1997
2016
2016

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 243 publications
(129 citation statements)
references
References 8 publications
2
122
0
5
Order By: Relevance
“…Urokinase was withdrawn from the US market because of a viral contamination but is available in Europe. The published trials have varied in their definition of catheter adequacy after treatment with a thrombolytic agent (minimal acceptable blood flow and duration of benefit) but reported success in 60 and 95% of catheters (97)(98)(99)(100)(101)(102). The benefit is often short-lived, with a median time of 4 wk before requiring another thrombolytic instillation (97,103).…”
Section: Treatment Of Catheter Thrombosis or Malfunctionmentioning
confidence: 99%
“…Urokinase was withdrawn from the US market because of a viral contamination but is available in Europe. The published trials have varied in their definition of catheter adequacy after treatment with a thrombolytic agent (minimal acceptable blood flow and duration of benefit) but reported success in 60 and 95% of catheters (97)(98)(99)(100)(101)(102). The benefit is often short-lived, with a median time of 4 wk before requiring another thrombolytic instillation (97,103).…”
Section: Treatment Of Catheter Thrombosis or Malfunctionmentioning
confidence: 99%
“…Since their development as an alternative to acute hemodialysis vascular access in the late 1900s, TCCs have generated controversy in the nephrology literature (8,9). TCCs are used as a bridge access device while awaiting maturation of an AVF in patients with severe comorbidities such as congestive heart failure and severe peripheral vascular disease, in the very elderly, in those with inadequate vascular anatomy, in those with limited life expectancy, and as a last resort in patients with multiple access failures (3).…”
Section: The Risks Of Tccsmentioning
confidence: 99%
“…Initial reports of tunneled, cuffed catheters reported low rates of bacteremia, but these were maintained in patients for a relatively short duration. In our original description, for example, median catheter use was only 8 wk, ranging from 3 wk to 5.4 mo (9). In this early report, only one episode of bacteremia occurred in 80 dual lumen catheters.…”
mentioning
confidence: 78%